{"id":25865,"date":"2011-10-04T06:06:50","date_gmt":"2011-10-04T06:06:50","guid":{"rendered":"https:\/\/drprem.com\/guide\/a-report-on-managing-asthama-during-pregnancy\/"},"modified":"2011-10-04T06:06:50","modified_gmt":"2011-10-04T06:06:50","slug":"a-report-on-managing-asthama-during-pregnancy","status":"publish","type":"post","link":"https:\/\/drprem.com\/globalhealthcare\/a-report-on-managing-asthama-during-pregnancy","title":{"rendered":"A report on managing Asthama during pregnancy"},"content":{"rendered":"
\n<\/a>\n<\/div>\n

<![CDATA[<\/p>\n

Measurement of fraction of exhaled nitric oxide (FENO) may help guide asthma management in pregnancy, according to the results of a double-blind, parallel-group, randomized controlled trial reported in the September 10 issue of *The Lancet.*<\/p>

\n<\/a>\n<\/div>\n\n

“Asthma exacerbations during pregnancy are common and can be associated with substantial maternal and fetal morbidity,” write Heather Powell, MMedSc, from the Centre for Asthma and Respiratory Diseases at University of Newcastle and Hunter Medical Research Institute in Newcastle, New South Wales, Australia, and colleagues from the Managing Asthma in Pregnancy study. “Treatment decisions based on sputum eosinophil counts reduce exacerbations in non-pregnant women with asthma, but results with …FENO to guide management are equivocal. We tested the hypothesis that a management algorithm for asthma in pregnancy based on FENO and symptoms would reduce asthma exacerbations.”<\/p>\n

Ref and Read more: https:\/\/www.medscape.com\/viewarticle\/749536<\/a><\/p>\n

]]> \t<\/p>\n

\n

\r\n <\/a><\/p>\r\n